

Evonik Financials & ESG KPI's

Financial KPI Group	P. 2
ESG KPI Group	P. 3
Division KPI	P. 4-8
Group Income Statement	P. 9-10
Group Balance Sheet	P. 11
Group Cash Flow Statement	P. 12
Group Net Financial Position	P. 13
Definitions	P. 14

As of Q3 2022 (November 08, 2022)

Financial KPI Group

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
External Sales	14,383	13,267	13,108	12,199	3,358	3,636	3,871	4,091	14,955	4,498	4,772	4,878
<i>Growth (%)</i>	13%	4%	-1%	-7%	4%	29%	33%	27%	23%	34%	31%	26%
<i>Volumes (%)</i>	3%	1%	-1%	-3%	5%	22%	16%	5%	11%	4%	-2%	-7%
<i>Prices (%)</i>	2%	5%	-2%	-3%	3%	10%	15%	19%	12%	22%	24%	17%
<i>Exchange Rates (%)</i>	-1%	-3%	1%	-2%	-4%	-5%	0%	1%	-2%	4%	6%	7%
<i>Other (incl. M&A; %)</i>	9%	1%	1%	1%	0%	2%	2%	2%	2%	4%	4%	9%
Adjusted EBITDA ¹	2,357	2,150	2,153	1,906	588	649	645	502	2,383	735	728	615
<i>Margin (%)</i>	16.4%	16.2%	16.4%	15.6%	17.5%	17.8%	16.7%	12.3%	15.9%	16.3%	15.2%	12.6%
EBIT	1,225	1,049	1,086	819	308	380	373	113	1,173	456	421	326
Adjusted EBIT	1,486	1,361	1,201	890	336	398	387	217	1,338	472	456	342
<i>Margin (%)</i>	10.3%	10.3%	9.2%	7.3%	10.0%	10.9%	10.0%	5.3%	8.9%	10.5%	9.6%	7.0%
Adjusted EPS	2.16	2.18	1.94	1.37	0.51	0.54	0.58	0.48	2.12	0.76	0.75	0.54
Free Cash Flow ²	511	526	717	780	312	101	524	13	950	133	-239	288
Cash Conversion Rate ³	22%	24%	33%	41%					40%			
Capex (Cash outflow for investment in intangible assets, pp&e)	1,040	948	880	956	182	171	177	335	865	176	165	229
Capital employed (annual average)	13,257	13,299	14,035	14,600					14,799			
ROCE (%) ⁴	11.2%	10.2%	8.6%	6.1%					9.0%			
Dividend (€)	1.15	1.15	1.15	1.15					1.17			
Employees (continuing operations)	36,523	32,623	32,423	33,106	32,745	32,661	32,891	33,004	33,004	33,151	33,235	33,836

¹ As from FY2018: continuing operations (excl. Methacrylates business); ² Excl. extraordinary carve out taxes of €245m in FY 2019 (MMA divestment); ³ Free cash flow conversion = FCF/adj. EBITDA;

⁴ ROCE 'restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

KPI Environment, Social, Governance

	2018 FY	2019 FY	2020 FY	2021 FY
Strategy & Growth				
Sales share with "Next Generation Solutions"	>30%	35%	37%	37% ^a
Value added in € million	4,740	5,994	4,069	4,707
Governance & Compliance				
Training rate fighting money laundering			82%	96%
Training rate antitrust law	74%	82%	88%	83%
Training rate fighting corruption	83%	91%	88%	92%
Training rate code of conduct	77%	89%	89%	89%
Internal investigations	90	113	130	136
Disciplinary measures	106	60	110	152
Value Chain & Products				
Procurement volume (in € billion)	9.9	9.4	8.0	10.4
Production output (million metric tons)	11.03	9.16	8.93	9.54
Use of renewable raw materials in production	9.7%	7.9%	8.5%	9.7%
Raw material suppliers covered by TfS assessments		66%	73%	69%
No. of sustainability audits (Evonik/TfS)	380	335	289	300
No. of sustainability assessments (Evonik/TfS)	1,621	1,160	1,334	1,521
R&D expenses (€ million)	459	428	433	464
The environment				
Scope 1 greenhouse gas emissions (thousands metric tons CO ₂)	5,689	4,923	4,860	4,826
Scope 2 greenhouse gas emissions (thousands metric tons CO ₂)	882	563	571 ^b	642
Scope 3 greenhouse gas emissions (million metric tons CO ₂)	21.0	17.8	20.0 ^b	21.9
% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO ₂) vs 2008	-31	-42	-43	-43
Total water intake (in million m ³)	490.2	523.6	561.4	599.7
Specific water intake (in m ³ freshwater / metric ton production)	31.8	32.4	36.5	41.3
Production waste (thousand metric tons)	393	325	311	354
Employees				
Early employee turnover	0.9%	0.9%	1.3%	2.2%
Continuing professional development per employee (hours)	16	8	12	5
Women at level "Executives" (circle 1)	12.3%	11.2%	15.9%	17.7%
Women at level "Senior management" (circle 2)	11.1%	12.6%	14.2%	17.6%
Women in management (circle 3)	25.6%	26.4%	27.1%	28.7%
Women in management (circles 1-3)	24.3%	25.2%	26.1%	27.9%
Safety				
Occupational health performance index	5.5	5.5	5.4	5.4
Accident frequency rate (no. of accidents / working hours) ^c	0.87	1.18	0.80	0.19
Incident frequency rate (no. of accidents / working hours) ^c	1.08	1.10	1.45	0.48

a: Update to follow until mid-year, ongoing analysis, no "fast close"; b: correction of data based on methodological improvements; c: reference value reduced from 1 mio. to now 200,000 working hours as from 2021 (for ESG KPI definitions please see separate "Definitions" page at the end of the file)

in € million	2017 FY ¹	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Sales	3,244	3,380	3,381	3,225	907	922	934	947	3,710	1,049	1,116	1,113
<i>Growth (%)</i>	53%	4%	0%	-5%	6%	23%	20%	12%	15%	16%	21%	19%
<i>Volumes (%)</i>	4%	3%	-1%	-3%	10%	24%	12%	0%	11%	-2%	-2%	-6%
<i>Prices (%)</i>	2%	3%	1%	0%	-1%	3%	7%	10%	5%	14%	18%	18%
<i>Exchange Rates (%)</i>	-1%	-2%	0%	-2%	-3%	-4%	1%	2%	-1%	3%	5%	6%
<i>Other (incl. M&A; %)</i>	48%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	1%
Adjusted EBITDA	857	908	886	857	273	242	224	181	920	252	263	243
<i>Margin (%)</i>	26.4%	26.9%	26.2%	26.6%	30.1%	26.2%	24.0%	19.1%	24.8%	24.0%	23.6%	21.8%
EBIT	n.a.	n.a.	712	683	230	200	179	130	739	205	214	194
Adjusted EBIT	676	744	716	681	230	198	181	130	739	205	214	194
<i>Margin (%)</i>	20.8%	22.0%	21.2%	21.1%	25.4%	21.5%	19.4%	13.7%	19.9%	19.5%	19.2%	17.4%
Capital expenditures	92	75	108	93	12	18	20	43	94	18	22	28
Capital employed (annual average)	3,494	3,912	4,396	4,244					4,168			
ROCE (%) ²	19.4%	19.0%	16.3%	16.0%					17.7%			
Employees	n.a.	n.a.	3,651	3,666	3,678	3,680	3,704	3,693	3,693	3,742	3,733	3,785

¹ First-time consolidation of acquired Air Products businesses as of 3 January 2017. Impact on sales: ~USD1.1 bn; adj. EBITDA: ~USD240 m

² ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Sales	3,002	3,036	2,922	2,992	780	838	931	1,008	3,557	1,038	1,027	1,062
Growth (%)	-5%	1%	-4%	2%	4%	13%	30%	28%	19%	33%	23%	14%
Volumes (%)	4%	5%	1%	2%	1%	13%	19%	8%	10%	4%	-6%	-10%
Prices (%)	-12%	1%	-5%	4%	10%	5%	11%	18%	11%	24%	21%	14%
Exchange Rates (%)	-1%	-5%	0%	-4%	-7%	-5%	0%	2%	-2%	6%	8%	9%
Other (incl. M&A; %)	4%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	1%
Sales Animal Nutrition	1,564	1,574	1,438	1,474	404	417	461	507	1,789	556	543	562
Sales Health & Care	1,438	1,462	1,484	1,518	376	421	470	501	1,768	481	484	500
Adjusted EBITDA	498	550	462	560	143	183	192	200	717	222	185	148
Margin (%)	16.6%	18.1%	15.8%	18.7%	18.3%	21.8%	20.6%	19.8%	20.2%	21.4%	18.0%	13.9%
EBIT	n.a.	n.a.	207	285	78	120	115	90	404	150	119	83
Adjusted EBIT	319	362	231	301	78	122	127	126	453	155	120	82
Margin (%)	10.6%	11.9%	7.9%	10.1%	10.0%	14.6%	13.6%	12.5%	12.7%	14.9%	11.7%	7.7%
Capital expenditures	338	442	214	139	22	34	30	78	164	25	42	64
Capital employed (annual average)	2,664	2,808	3,974	3,914					3,893			
ROCE (%) ¹	12.0%	12.9%	5.8%	7.7%					11.6%			
Employees	n.a.	n.a.	5,322	5,295	5,281	5,323	5,386	5,453	5,453	5,540	5,594	5,680

¹ ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

in € million	2017 FY ¹	2018 FY ²	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Sales	3,148	3,382	3,371	3,235	909	975	1,002	1,032	3,918	1,181	1,237	1,259
Growth (%)	1%	7%	0%	-4%	6%	35%	27%	19%	21%	30%	27%	26%
Volumes (%)	7%	-3%	-4%	-7%	9%	33%	18%	7%	16%	9%	4%	-1%
Prices (%)	1%	7%	3%	-1%	-1%	0%	6%	10%	4%	16%	21%	20%
Exchange Rates (%)	-1%	-2%	0%	-2%	-4%	-4%	0%	1%	-2%	4%	3%	6%
Other (incl. M&A; %)	-6%	5%	1%	6%	2%	6%	3%	1%	3%	2%	-1%	1%
Sales Inorganics	2,117	2,325	2,312	2,315	631	686	700	738	2,754	843	898	911
Sales Polymers	1,031	1,057	1,059	920	278	289	302	294	1,164	338	339	348
Adjusted EBITDA	565	631	651	529	173	176	177	123	650	197	198	177
Margin (%)	17.9%	18.7%	19.3%	16.4%	19.0%	18.1%	17.7%	11.9%	16.6%	16.7%	16.0%	14.1%
EBIT	n.a.	n.a.	443	226	101	103	102	40	346	124	122	99
Adjusted EBIT	415	434	433	270	108	111	111	45	374	127	126	103
Margin (%)	13.2%	12.8%	12.8%	8.3%	11.9%	11.4%	11.1%	4.4%	9.5%	10.8%	10.2%	8.2%
Capital expenditures	286	243	303	466	59	87	78	155	379	45	60	69
Capital employed (annual average)	2,226	2,565	3,651	4,244					4,637			
ROCE (%) ³	18.6%	16.9%	11.9%	6.4%					8.1%			
Employees	n.a.	n.a.	7,065	7,874	7,783	7,765	7,731	7,742	7,742	7,826	7,846	7,919

¹ First-time consolidation of acquired Huber business as of 1 September 2017 (FY 2016 sales: ~USD300 m; adj. EBITDA: ~USD60 m)

² First-time consolidation of acquired PeroxyChem business as of 3 February 2020 (FY 2019 sales: ~USD300 m; adj. EBITDA: ~USD64 m); First-time consolidation of Porocel business as of 3 November 2020 (FY 2019 sales: ~USD100 m; adj. EBITDA: ~USD23 m)

³ ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Sales	2,609	2,789	2,634	1,983	580	708	784	840	2,911	947	1,043	903
<i>Growth (%)</i>	11%	7%	-6%	-25%	-1%	62%	77%	63%	47%	63%	47%	15%
<i>Volumes (%)</i>	-2%	-1%	0%	-8%	-2%	20%	19%	6%	10%	6%	-7%	-16%
<i>Prices (%)</i>	14%	9%	-7%	-17%	7%	50%	58%	54%	40%	51%	45%	23%
<i>Exchange Rates (%)</i>	-1%	-2%	1%	0%	-6%	-8%	-1%	2%	-3%	6%	9%	8%
<i>Other (incl. M&A; %)</i>	0%	1%	0%	0%	0%	0%	1%	1%	0%	1%	0%	0%
Adjusted EBITDA	290	243	248	88	42	99	97	80	317	97	163	74
<i>Margin (%)</i>	11.1%	8.7%	9.4%	4.4%	7.2%	14.0%	12.4%	9.5%	10.9%	10.2%	15.6%	8.2%
EBIT	n.a.	n.a.	101	-48	10	67	60	33	169	66	127	33
Adjusted EBIT	201	158	117	-45	10	66	63	50	188	66	129	39
<i>Margin (%)</i>	7.7%	5.7%	4.4%	-2.3%	1.7%	9.3%	8.0%	6.0%	6.5%	7.0%	12.4%	4.3%
Capital expenditures	92	57	55	49	8	11	14	30	63	12	12	16
Capital employed (annual average)	818	919	1,296	1,293					1,209			
ROCE (%) ¹	24.5%	17.2%	9.0%	-3.5%					15.6%			
Employees	n.a.	n.a.	1,645	1,798	1,810	1,791	1,962	1,964	1,964	1,975	1,998	2,031

¹ ROCE restated since 2019: Goodwill relating to Evonik Degussa acquisition by RAG AG (before Evonik foundation), which was previously reported in "Other" is now allocated to the divisions

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Sales	712	680	800	764	182	193	220	264	859	283	349	541
<i>Growth (%)</i>	2%	-4%	18%	-4%	-9%	8%	15%	36%	12%	55%	82%	146%
Adjusted EBITDA	-238	-182	-94	-128	-43	-51	-45	-82	-221	-33	-81	-27
EBIT	n.a.	n.a.	-377	-327	-111	-110	-83	-180	-485	-89	-161	-83
Adjusted EBIT	-378	-336	-296	-317	-90	-99	-95	-134	-416	-81	-133	-76
Capital expenditures	173	151	162	209	81	21	35	29	165	76	29	52
Employees	n.a.	n.a.	14,740	14,473	14,193	14,102	14,108	14,152	14,152	14,068	14,064	14,421

Group Income Statement

in € million	2017 FY	2018 FY	2019 FY	2020 FY ¹	2021 Q1 ¹	2021 Q2 ¹	2021 Q3 ¹	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Sales	14,383	13,267	13,108	12,199	3,358	3,636	3,871	4,091	14,955	4,498	4,772	4,878
Cost of sales	-9,905	-9,271	-9,413	-8,865	-2,371	-2,564	-2,807	-3,185	-10,925	-3,277	-3,559	-3,784
Gross profit on sales	4,478	3,996	3,695	3,334	987	1,072	1,064	906	4,030	1,221	1,213	1,094
Selling expenses	-1,695	-1,563	-1,511	-1,501	-392	-416	-436	-473	-1,717	-492	-512	-540
Research and development expenses	-476	-437	-428	-433	-104	-111	-118	-131	-464	-112	-113	-115
General administrative expenses	-714	-599	-568	-531	-135	-123	-148	-140	-546	-130	-154	-129
Other operating income & expenses	-378	-358	-107	-65	-50	-44	9	-51	-138	-33	-18	15
Result from investments recognized at equity	10	10	5	15	2	2	2	2	8	2	5	1
Income before financial result and income taxes, continuing operations = EBI¹	1,225	1,049	1,086	819	308	380	373	113	1,173	456	421	326
Financial Result	-203	-155	-132	-135	-21	-40	-37	10	-88	-12	4	-21
Income before income taxes, continuing operations	1,022	894	954	684	287	340	336	123	1,085	444	425	305
Income taxes	-292	-186	-180	-181	-88	-113	-100	-16	-316	-126	-123	-90
Income after taxes, continuing operations	730	708	774	503	199	227	236	107	769	318	302	215
Income after taxes, discontinued operations	0	246	1,353	-24	-7	-3	4	4	-2	-	-	-
Income after taxes	730	954	2,127	479	192	224	240	111	767	318	302	215
thereof attributable to non-controlling interests	17	22	21	14	6	6	5	5	21	4	5	1
Shareholders of EVONIK Industries AG (net income)	713	932	2,106	465	186	218	235	106	746	314	297	214
EPS	1.53	2.00	4.52	1.00	0.40	0.47	0.50	0.23	1.60	0.67	0.64	0.46

¹ Restated as adjustments were allocated to respective line items (instead of allocated to other operating income & expenses)

Group Adjusted Income Statement

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Sales	14,383	13,267	13,108	12,199	3,358	3,636	3,871	4,091	14,955	4,498	4,772	4,878
Adjusted EBITDA	2,357	2,150	2,153	1,906	588	649	645	502	2,383	735	728	615
Depreciation and amortization	-871	-789	-952	-1,016	-252	-251	-258	-285	-1,045	-263	-272	-273
Adjusted EBIT	1,486	1,361	1,201	890	336	398	387	217	1,338	472	456	342
Adjusted net financial result	-176	-151	-185	-146	-21	-50	-37	11	-97	-12	4	-21
Depreciation and amortization on intangible assets	129	143	136	149	36	35	37	54	162	41	41	39
Adjusted income before income taxes, continuing operations	1,439	1,353	1,152	893	351	383	387	282	1,403	501	501	360
Adjusted income taxes, continuing operations	-415	-317	-229	-239	-106	-124	-113	-54	-396	-141	-145	-106
Adjusted income after taxes	1,024	1,036	923	654	245	259	274	229	1,007	360	356	254
Adjusted non-controlling interest	-17	-22	-21	-14	-6	-6	-5	-4	21	-4	-5	-1
Adjusted net income	1,007	1,014	902	640	239	253	269	224	986	356	351	253
Adjusted EPS	2.16	2.18	1.94	1.37	0.51	0.54	0.58	0.48	2.12	0.76	0.75	0.54

Adjustments

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Restructuring	-25	-204	-18	-14	-3	-10	-5	-3	-20	0	-23	-3
Impairment losses/reversal of impairment losses	-82	7	-47	4	0	0	0	-27	-27	0	0	0
Acquisition / divestment of shareholdings	-89	-31	-30	-37	-4	-2	-5	-2	-13	-2	-3	-3
Other	-65	-84	-20	-24	-21	-6	-4	-72	-105	-14	-9	-10
=Adjustments	-261	-312	-115	-71	-28	-18	-14	-104	-165	-16	-35	-16

Group Balance Sheet

Assets

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 FY	2022 Q1	2022 Q2	2022 Q3
Intangible assets	6,105	6,134	5,858	5,877	5,990	5,891	5,982	6,045	6,063	6,204	6,332
Property, plant and equipment	6,495	6,785	6,435	6,588	6,630	6,648	6,707	6,963	6,974	7,071	7,239
Right of use assets (capitalized leasing)			640	668	661	640	623	608	616	748	896
Investments recognized at equity	47	46	45	75	81	78	80	81	79	82	83
Financial assets	327	233	625	607	566	578	559	581	568	451	403
Deferred tax assets	1,226	1,419		2,004	1,793	1,715	1,641	1,755	1,589	1,134	1,091
Other income tax assets	14	16		13	14	14	15	16	16	16	18
Other receivables	296	56	82	102	102	127	160	125	119	112	79
Non-current assets	14,510	14,689	15,415	15,934	15,837	15,691	15,767	16,174	16,024	15,818	16,141
Inventories	2,038	2,304	1,884	1,806	1,996	2,151	2,351	2,548	2,863	3,279	3,450
Other income tax assets	154	180	325	211	198	200	135	199	157	156	151
Trade accounts receivable	1,755	1,686	1,569	1,455	1,721	1,799	1,877	1,954	2,345	2,482	2,327
Other receivables	313	295	387	231	304	346	353	382	474	527	595
Financial assets	166	140	1,278	697	435	295	379	571	573	487	441
Cash and cash equivalents	1,004	988	1,165	563	936	520	821	456	647	731	1,078
Current assets	5,430	5,593	6,608	4,963	5,590	5,311	5,916	6,110	7,059	7,662	8,042
Assets held for sale	0	0	0	0	0	0	0	0	0	0	98
Current assets	5,430	5,593	6,608	4,963	5,590	5,311	5,916	6,110	7,059	7,662	8,140
Total assets	19,940	20,282	22,023	20,897	21,427	21,002	21,683	22,284	23,083	23,480	24,281

Liabilities

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 FY	2022 Q1	2022 Q2	2022 Q3
Issued capital	466	466	466	466	466	466	466	466	466	466	466
Reserves	6,965	7,263	8,504	7,546	8,449	8,216	8,698	8,823	9,712	10,671	11,247
Equity attributable to shareholders of Evonik Industries AG	7,431	7,729	8,970	8,012	8,915	8,682	9,164	9,289	10,178	11,137	11,713
Equity attributable to non-controlling interests	88	96	90	87	84	77	82	83	83	84	84
Total equity	7,519	7,825	9,060	8,099	8,999	8,759	9,246	9,372	10,261	11,221	11,797
Provisions for pensions and other post-employment benefits	3,817	3,732	3,967	4,618	3,879	3,770	3,569	3,766	3,166	1,780	1,655
Other provisions	788	855	779	715	641	673	679	657	631	639	628
Deferred tax liabilities	541	557	537	586	580	582	591	628	644	656	678
Other income tax liabilities	225	223	320	275	253	261	260	195	202	216	209
Financial liabilities	3,706	3,689	3,713	3,564	3,592	3,553	3,631	3,531	2,795	3,649	4,043
Other payables	57	47	93	114	117	112	138	143	141	132	164
Non-current liabilities	9,134	9,103	9,409	9,872	9,062	8,951	8,868	8,920	7,579	7,072	7,377
Other provisions	968	1,047	778	744	815	626	789	892	984	660	739
Other income tax liabilities	50	64	59	136	209	229	266	211	230	226	225
Financial liabilities	438	395	918	434	411	426	378	477	1,373	1,565	1,521
Trade accounts payable	1,449	1,493	1,324	1,273	1,470	1,496	1,600	2,022	2,139	2,173	2,013
Other payables	382	355	475	339	461	515	536	390	517	563	596
Current liabilities	3,287	3,354	3,554	2,926	3,366	3,292	3,569	3,992	5,243	4,624	5,094
Liabilities associated with assets held for sale	0	0	0	0	0	0	0	0	0	0	13
Current liabilities	3,287	3,354	3,554	2,926	3,366	3,292	3,569	3,992	5,243	5,187	5,107
Total equity and liabilities	19,940	20,282	22,023	20,897	21,427	21,002	21,683	22,284	23,083	23,480	24,281

Group Cash Flow Statement

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2021 FY	2022 Q1	2022 Q2	2022 Q3
Income before financial result and income taxes, continuing operations = EBIT	1,225	1,049	1,086	819	308	380	373	113	1,173	456	421	326
Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets	923	787	984	1,018	251	250	260	312	1,073	264	274	275
Result from investments recognized at equity	-10	-10	-5	-15	-2	-2	-2	-2	-8	-2	-4	-2
Gains/losses on disposal of non current assets	-73	3	-13	-10	-1	22	0	22	43	1	2	0
Change in inventories	-97	-242	129	70	-158	-161	-181	-175	-675	-278	-336	-123
Change in trade accounts receivable	-56	75	41	54	-229	-91	-62	-67	-449	-362	-100	192
Change in trade accounts payable and current advance payments received from customers	192	15	-62	-30	210	30	84	356	680	150	15	-184
Change in provisions for pensions and other post-employment benefits	-202	-229	-60	-14	25	17	10	31	83	21	9	-5
Change in other provisions	-6	158	-294	-133	47	-103	163	100	207	66	-289	85
Change in miscellaneous assets/liabilities	22	26	-15	33	67	-18	40	-113	-23	34	7	12
Cash inflows/outflows from interest	-65	-	-	-	-	-	-	-	-	-	-	-
Cash inflows from dividends	11	12	15	27	11	6	1	1	19	11	4	0
Tax payments relating to carve-out of the methacrylates business	-	-	-245	-	-	-	-	-	-	-	-	-
Cash inflows/outflows for income taxes	-313	-170	-209	-83	-35	-58	15	-230	-308	-52	-77	-59
Cash flow from operating activities, continuing operations	1,551	1,474	1,352	1,736	494	272	701	348	1,815	309	-74	517
Cash flow from operating activities, discontinued operations	0	286	-31	-9	0	0	0	0	0	0	0	0
Cash flow from operating activities	1,551	1,760	1,321	1,727	494	272	701	348	1,815	309	-74	517
Cash outflows for investments in intangible assets, property, plant and equipment, investment property	-1,040	-948	-880	-956	-182	-171	-177	-335	-865	-176	-165	-229
Cash outflows for investments in shareholdings	-4,137	-39	-427	-474	-6	0	-42	-36	-85	-11	-1	-6
Cash outflows for loss from divestments of shareholdings	-	-	-	-	-78	-67	0	0	-145	-	-	-
Cash outflows for divestments in intangible assets, property, plant and equipment,	-	-	-	-	-	-	-	-21	-21	-	-	-
Cash inflows from divestments of intangible assets, property, plant and equipment, investment property	12	16	25	45	7	1	0	1	9	3	-	4
Cash inflows/outflows from divestments of businesses and other shareholdings	-10	68	2,208	65	-	1	1	0	2	-	-	-
Cash inflows/outflows relating to securities, deposits and loans	17	-24	-1,223	720	204	73	-99	-155	23	-9	91	38
Cash inflows from interest	-	43	52	30	2	5	3	2	12	3	4	5
Cash flow from investing activities, continuing operations	-5,181	-884	-245	-570	-53	-158	-315	-544	-1,070	-190	-71	-188
Cash flow from investing activities, discontinued operations	0	-89	-47	0	0	0	0	0	0	0	0	0
Cash flow from investing activities	-5,181	-973	-292	-570	-53	-158	-315	-544	-1,070	-190	-71	-188
Cash inflows/outflows relating to capital contributions	0	2	4	2	-	0	0	0	0	-	-	-
Cash outflows for dividends to shareholders of Evonik Industries AG	-536	-536	-536	-536	0	-536	0	0	-536	0	-545	0
Cash outflows for dividends to non-controlling interests	-14	-16	-12	-16	-6	-14	0	-1	-21	-2	-8	-1
Cash inflows/outflows from changes in ownership interests in subsidiaries without loss of control	0	0	0	0	0	0	0	0	0	0	0	-5
Cash outflows for the purchase of treasury shares	-19	-17	-17	-16	-15	0	0	0	-15	-16	0	0
Cash inflows from the sale of treasury shares	20	13	13	12	0	12	0	0	12	0	12	0
Cash inflows from the addition of financial liabilities	700	61	110	1,039	81	3	533	38	655	156	926	426
Cash outflows for repayment of financial liabilities	-201	-192	-295	-2,156	-129	-56	-573	-190	-948	-60	-81	-331
Cash inflows/outflows in connection with financial transactions	73	8	-1	14	12	77	-5	7	91	1	-65	-39
Cash outflows for interest	-	-121	-114	-77	-16	-18	-38	-22	-94	-14	-9	-23
Cash flow from financing activities, continuing operations	23	-798	-848	-1,734	-73	-532	-83	-168	-856	65	230	27
Cash flow from financing activities, discontinued operations	0	-3	-8	0	0	0	0	0	0	0	0	0
Cash flow from financing activities	23	-801	-856	-1,734	-73	-532	-83	-168	-856	65	230	27
Change in cash and cash equivalents	-3,607	-14	173	-577	368	-418	303	-364	-111	184	85	356
Cash and cash equivalents as of beginning of period	4,623	1,004	988	1,165	563	936	520	821	563	456	647	731
Change in cash and cash equivalents	-3,607	-14	173	-577	368	-418	303	-364	-111	184	85	356
Changes in exchange rates and other changes in cash and cash equivalents	-12	-2	4	-25	5	2	-2	-1	4	7	-1	4
Cash and cash equivalents as of end of period	1,004	988	1,165	563	936	520	821	456	456	647	731	1,091
Cash and cash equivalents included in assets held for sale	0	0	0	0	0	0	0	0	0	0	0	13
Cash and cash equivalents as on the balance sheet as of end of period	1,004	988	1,165	563	936	520	821	456	456	647	731	1,078

Group Net Financial Position

in € million	2017 FY	2018 FY	2019 FY	2020 FY	2021 Q1	2021 Q2	2021 Q3	2021 FY	2022 Q1	2022 Q2	2022 Q3
Non-current financial liabilities	-3,694	-3,683	-3,712	-3,564	-3,588	-3,549	-3,627	-3,527	-2,776	-3,626	-4,001
Current financial liabilities	-351	-230	-806	-368	-326	-337	-235	-232	-1,106	-1,282	1,180
Financial debt	-4,045	-3,913	-4,518	-3,932	-3,914	-3,886	-3,862	-3,759	-3,882	-4,908	-5,181
- Cash and cash equivalents	1,004	988	1,165	563	936	520	821	456	647	731	1,078
- Current securities	9	8	1,203	466	254	196	300	446	441	341	296
- Other financial assets	9	10	9	17	20	0	0	0	0	0	0
Financial assets	1,022	1,006	2,377	1,046	1,210	716	1,121	902	1,088	1,072	1,374
Net financial debt/cash as stated on the balance sheet	-3,023	-2,907	-2,141	-2,886	-2,704	-3,170	-2,741	-2,857	-2,794	-3,836	-3,807
Net financial debt/cash, discontinued operations											
Net financial debt/cash including discontinued operations		-2,907	-2,141	-2,886	-2,704	-3,170	-2,741	-2,857	-2,794	-3,836	-3,807

Financial KPI Definitions

Adjusted EBIT	Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.
Adjusted EBITDA	Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.
Adjusted net income	We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.
Adjustments	Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.
Free Cash Flow	The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.
ROCE	The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

ESG KPI Definitions

Value added in € million	We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.
Sales share with "Next Generation Solutions"	Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA) For more information please see Evonik website: Responsibility - Value Chain & Products - Sustainability Analysis
Internal Investigations	Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.
Disciplinary Measures	Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.
Raw Material Suppliers Covered by TFS Assessments	This number indicates how many raw material suppliers have been covered by TFS assessments in that year. The chemical industry set up the Together for Sustainability (TFS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.
Greenhouse Gas Emissions	Scope 1: Evonik's direct energy and process-related emissions; Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach); Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, energy requirements for offices and emissions from the disposal and recycling of products sold.
Early Employee Turnover	Turnover of newly hired employees within the first year of employment
Management circles/ levels	Management circle 1 = executive functions, i.e., top management functions in the Evonik Group Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions
Occupational Health Performance Index	This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.
Specific water intake <small>in m3 freshwater per metric ton production</small>	Freshwater usage in relation to production.
Total water intake	Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).